BEMPETOL EZ Tablet is an advanced fixed-dose combination formulation containing Bempedoic Acid and Ezetimibe, designed to provide enhanced LDL-C reduction in patients with hypercholesterolemia or mixed dyslipidemia. It is ideal for adults requiring additional lipid control beyond what is achievable with statins alone, or for those who are statin-intolerant. By targeting two different cholesterol pathways—Bempedoic Acid inhibiting ATP citrate lyase in the liver and Ezetimibe reducing intestinal absorption of cholesterol—BEMPETOL EZ delivers a synergistic and effective lipid-lowering action. Manufactured under strict WHO-GMP and ISO-compliant facilities, this dual therapy enhances cardiovascular protection while maintaining an excellent safety profile.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

BEMPETOL EZ Tablet is a modern, fixed-dose oral pharmaceutical preparation combining two well-established lipid-lowering agents—Bempedoic Acid and Ezetimibe—into a single, once-daily formulation. This combination is intended for the treatment of adults with primary hypercholesterolemia, both familial and non-familial types, and mixed dyslipidemia who require additional lowering of low-density lipoprotein cholesterol (LDL-C). It is also recommended for patients who are unable to tolerate statins or for whom statin therapy alone does not provide sufficient lipid control.

Bempedoic Acid is a novel, first-in-class ATP citrate lyase (ACL) inhibitor that works upstream of HMG-CoA reductase in the cholesterol biosynthetic pathway. Once ingested, it is activated in the liver by very-long-chain acyl-CoA synthetase 1 (ACSVL1), ensuring liver-specific action and avoiding muscle tissue exposure. This unique mechanism of action reduces hepatic cholesterol synthesis and upregulates LDL receptors, resulting in enhanced clearance of circulating LDL particles. As it does not affect skeletal muscle, the incidence of muscle-related side effects is significantly lower than that seen with statin therapy, making it ideal for statin-intolerant individuals.

Ezetimibe, on the other hand, inhibits the absorption of cholesterol from the small intestine by targeting the Niemann-Pick C1-like 1 (NPC1L1) transporter on the brush border of enterocytes. It reduces the incorporation of dietary and biliary cholesterol into chylomicrons, leading to reduced delivery of cholesterol to the liver. As a result, hepatic LDL receptor expression increases, enhancing LDL-C clearance from the bloodstream.

The combination of Bempedoic Acid and Ezetimibe in BEMPETOL EZ Tablet provides a dual mechanism of action—blocking cholesterol production in the liver and its absorption in the intestine. This synergy leads to superior LDL-C reduction, typically around 35% to 40%, even in the absence of statins. In patients on maximally tolerated statin therapy, the addition of BEMPETOL EZ can further reduce LDL-C by up to 50%, helping them achieve the aggressive targets recommended in current cardiovascular prevention guidelines such as those from the ACC, ESC, and NLA.